


**Research Group for
Biological Arms Control**



2013 Reader on Publicly Available CBMs

December 2013

About this Reader

The exchange of information under the Biological Weapons Convention (BWC) in the form of the Confidence Building Measures (CBMs) remains the only permanent transparency building tool of the BWC.

This Reader, as its forerunners, presents information on CBM-related developments and the data provided in the openly available CBMs of the current year. The CBM Reader aims to underline the importance of participating in the CBM data exchange as the only established permanent transparency tool for the BWC and to highlight the particular efforts of an increasing number of states to foster transparency by making their CBM submissions available to the public. The CBM Reader series is prepared as part of our efforts to increase transparency around bioweapon relevant activities globally. Such transparency is indispensable for building confidence in compliance with the BWC and must extend to all stakeholders including civil society. For more information please visit www.biological-arms-control.org/projects_improvingthecbms.html.

Development of the CBM regime in 2013

On the 7th Review Conference in 2011 BWC States Parties decided to address CBMs in the 2012 and 2013 the Meetings of Experts and the Meetings of States Parties. As result of the discussions in the actual ISP a possible update of the CBM forms (that date back to the year 1992) could be envisaged. Figures showed in this reader illustrate also the need for a debate how a better participation in the mechanism could be reached. The debates in the precedent ISP meetings show that these issues still have some potential for development. Decisions can, however, not be taken before the 8th Review Conference in 2016.

Facts about the BWC and its CBMs

BWC States Parties: 170

New BWC States Parties in 2013: 4

States Parties with national contact points: 77

CBMs submitted in 2013: 58 as of 27 November 2013

First-time CBM submissions in 2013: 0

Number of states having participated in the CBM data exchange in 25 years: 112

CBM-specific publications in 2013

United Kingdom (2013) Confidence-building Measures: next steps to enable fuller participation, BWC/MSP/2013/MX/WP.3, 29 July 2013

Canada (2013) Improving participation in the Confidence-Building Measure system, BWC/MSP/2013/MX/WP.7, 5 August 2013

USA (2013) Making the most of the Confidence-building Measures, BWC/MSP/2013/MX/WP.9, 5 August 2013

Switzerland (2013) Confidence-Building Measures: enabling fuller participation, BWC/MSP/2013/MX/WP.13, 9 August 2013

Participation in the CBM regime in 2013


In 2013, participation in the CBM data exchange decreased considerably. As of 27 November 2013, only 58 BWC states parties had submitted their CBM. The overall status of the CBMs remains weak as well. Since the beginning of the data exchange in 1987, the annual level of participation was never higher than 44 per cent of the BWC states parties. In total, 115 countries submitted a CBM at least once. This means that 55 BWC states parties have yet to submit their first CBM declaration. Continuity in states' participation also remains weak: 25 countries have submitted a CBM annually for the last 10 years, 45 countries have done so for the last five years, and 32 countries have submitted a CBM only once or twice since 1987.

First-time submissions in 2013: None

CBM submissions in 2013 (States in bold made their CBM available to the public.):

1. Argentina	13. Cuba	24. Iraq	35. Nicaragua	47. Slovakia
2. Australia	14. Czech Republic	25. Italy	36. Norway	48. Slovenia
3. Austria	15. Denmark	26. Japan	37. Poland	49. South Africa
4. Belarus	16. Ecuador	27. Latvia	38. Portugal	50. Spain
5. Belgium	17. Estonia	28. Lybia	39. Qatar	51. Sweden
6. Bhutan	18. Finland	29. Liechtenstein	40. Rep. Korea	52. Switzerland
7. Brazil	19. France	30. Lithuania	41. Rep. Moldova	53. Turkey
8. Bulgaria	20. Georgia	31. Mexico	42. Romania	54. Ukraine
9. Canada	21. Germany	32. Morocco	43. Russia	55. UK
10. Chile	22. Greece	33. Netherlands	44. Senegal	56. USA
11. China	23. Hungary	34. New Zealand	45. Serbia	57. Uzbekistan
12. Croatia			46. Singapore	58. Yemen

Figure 1. CBM submissions per year between 1987 and 2013 (Numbers in this figure differ from numbers provided by the Implementation Support Unit. This is due to differences in counting states that were formerly part of other states, such as the former republics of the Soviet Union. This figure provides the actual number of CBM declarations submitted in the respective year.)



Publicly available CBMs in 2013

As of 20 November 2013, 25 countries have made their 2013 CBM declarations publicly available, a slight decline compared to previous years. 22 of the 25 publicly available CBMs can be found on the website of the Implementation Support Unit (ISU) (www.unog.ch/bwc/cbms): Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Estonia Finland, Germany, Greece, Japan, Latvia, Lithuania, New Zealand, Norway, Portugal, Romania, Republic of Moldova, Sweden, Switzerland, United Kingdom and the USA. Three CBMs were provided directly to the Hamburg Research Group: Bulgaria, Netherlands and Qatar

At least Belgium and the USA provided two separate versions of their CBMs, one for the restricted part of the ISU website and one for the public.

Figure 2. Number of publicly available CBMs 2006-2013




Table 1. Countries that made their CBM declarations publicly available, 2006-2013

Country	2006	2007	2008	2009	2010	2011	2012	2013
Albania					x			
Australia	x	x	x	x	x	x	x	x
Austria				x	x	x	x	x
Bangladesh			x					
Belgium						x	x	x
Brazil					x			
Bulgaria		x	x		x	x	x	x
Canada						x	x	x
Croatia	x							
Cyprus						x	x	
Czech Republic	x			x	x	x	x	x
Denmark		x	x		x	x	x	
Ecuador						x		
Estonia					x	x		x
Finland	x	x	x	x	x	x	x	x
Georgia				x	x	x		
Germany	x	x	x	x	x	x	x	x
Greece						x	x	x
Japan							x	x
Ireland	x	x	x	x	x	x		
Latvia	x			x		x	x	x
Lichtenstein		x	x	x	x	x		x
Lithuania	x	x	x	x	x	x	x	x
Madagascar							x	
Malaysia	x					x		
Netherlands								x
New Zealand	x	x	x		x	x	x	x
Norway			x		x	x	x	x
Poland					x			
Portugal					x	x	x	x
Quatar							x	x
Repuclic of Moldova							x	x
Romania			x	x	x	x	x	x
Serbia							x	
Senegal					x			
Slovakia		x						
Sweden	x	x	x	x	x	x	x	x
Switzerland	x	x	x	x	x	x	x	x
Thailand					x	x	x	
Turkey						x	x	
United Kingdom	x	x	x	x	x	x	x	x
Ukraine						x	x	
USA					x	x	x	x
Total	13	13	15	14	25	30	29	24

As shown in Table 1 above, a decreasing number of states make their CBM declarations publicly available. 38 countries have done so at least once since 2006. Many states make their CBMs publicly available in an erratic way. Only 10 of the 24 states that have made their CBMs publicly available in 2013 have done so annually for the past three years: Australia, Austria, Czech Republic, Finland, Germany, Lithuania, Romania, Sweden, Switzerland and the United Kingdom. No explanation readily offers itself for why many states make their CBMs publicly available in one year but not in another.

Summary of data in publicly available 2013 CBM declarations

A summary of the data declared in the 24 publicly available CBMs of 2013 is provided in the table below. More detailed information can be found in the Annex to this Reader. 26 maximum biological containment facilities were declared in publicly available CBMs in 2013, four of which were partially or wholly funded by ministries of defence. 18 of the 24 countries making their 2013 CBM publicly available declared having a biodefence programme; they provided information on 65 biodefence facilities. And lastly, eleven unusual disease outbreaks and 67 vaccine production facilities were declared in the 24 publicly available CBMs of 2013.

Table 2. Summary of data in publicly available CBM declarations, 2013

Form A, part 1:	Number of maximum biological containment facilities (BSL-4 or equivalent) declared.
Form A, part 2 (i):	Does the state party declare having a biodefence programme?
Form A, part 2 (iii):	Number of biodefence facilities declared.
Form B (ii):	Number of unusual disease outbreaks declared.
Form F:	Does the state party declare having a past offensive and/or defensive programme?
Form G:	Number of vaccine production facilities declared.
ND:	“Nothing to declare” indicated in Form 0.
NN:	“Nothing new to declare” indicated in Form 0.

Country	Form A, part 1	Form A, part 2 (i)	Form A, part 2 (iii)	Form B (ii)	Form F (off/def)	Form G
Australia	4	yes	1	0	no/no	3
Austria	0	yes	1	0	no/no	0
Belgium	ND	yes	4	2	ND	1
Bulgaria	0	yes	1	0	no/no	1
Canada	2	yes	2	0	yes/yes	13
Czech Republic	2	no	2	ND	NN	5
Estonia	ND	no	ND	ND	no/no	ND
Finland	0	yes	1	ND	ND	ND
Germany	3 ¹	yes	4	1	NN	6
Greece	0	no	ND	ND	no/no	ND
Japan	2	yes	1	ND	NN	7
Latvia	0	yes	1	ND	<i>No data provided</i>	ND
Liechtenstein	NN	no	NN	0	NN	NN
Lithuania	0	no	ND	ND	no/no	NN
Netherlands	1	yes	1	2	no/yes	6
New Zealand	0	no	ND	NN	no/no	ND
Norway	0	yes	1	ND	no/no	3
Portugal	0	yes	1	ND	ND	1
Republic of Moldova	0	yes	1	0	NN	ND
Romania	0	NN	1	ND	ND	4
Sweden	1	yes	1	0	no/no	2
Switzerland	1 ²	yes	13	0	no/yes	2
United Kingdom	7 ³	yes	1	1	yes/yes	3
USA	7	yes	29	5	NN	10

¹ Includes one maximum containment facility not suitable for work with human pathogens.

² The BSL-4 unit is approved for diagnostic purposes only.

³ Includes three animal pathogen maximum containment facilities designated SAPO (Specified Animal Pathogens Order).

ANNEX

The following table summarizes the data declared in **CBM Form A, part 1**, of the publicly available CBM submissions from 2011 and compares them with the information in publicly available CBMs from 2006 to 2010. The table provides the names and locations of facilities declared in CBM Form A, part 1, their containment levels, the year(s) they were declared, and whether the facilities were wholly or partly funded by ministries of defence (MoD). Grey cells indicate that there was no CBM submission or that it was not made publicly available in the respective year. “ND” indicates that the state ticked the “Nothing to declare” box in Form 0. “NN” indicates that the state ticked the “Nothing new to declare” box in Form 0. “-” indicates that no data were provided.

Country	Name and location of facilities declared in CBM Form A, part 1	Cont. level	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	MoD funded in 2013?
Australia	1. Australian Animal Health Laboratory (Geelong)	BL4	x	x	x	x	x	x	x	x	no
	2. National High Security Quarantine Laboratory (North Melbourne)	BL4	x	x	x	x	x	x	x	x	no
	3. Queensland Health and Forensic Scientific Services (Cooper Plains)	BL4	x	x	x	x	x	x	x	x	no
	4. Emerging Infectious Disease and Biohazard Response Unit (Westmead)	BL4	-	-	x	x	x	x	x	x	no
Austria	1. Federal Ministry of Defence and Sports/Div NBC & Environmental Protection Technology (Vienna)	BL3				x	x	x	x	x	wholly
Belgium	<i>Nothing to declare</i>	n.a.						ND	ND	ND	n.a.
Bulgaria	1. National Center of Infectious and Parasitic Diseases (Sofia)	BL3		x	x		x	x	x	x	no
	2. National Diagnostic and Research Veterinary Medical Institute (Sofia)	BL3		-	-		x	x	-	-	no
Canada	1. National Microbiology Laboratory (Winnipeg)	BL4						x	x	x	no
	2. National Centre for Foreign Animal Disease (Winnipeg)	BL4						x	x	x	no
Cyprus	<i>Nothing new to declare</i>	BL2						ND	n.a.		n.a.
Czech Republic	1. State Veterinary Institute (Jihlava)	BL3	-			-	x	x	-	NN	n.a.
	2. State Veterinary Institute (Lysolaje)	BL3	-			-	-	x	-	NN	n.a.
	3. Tekro, spol.s.r.o. (Uničov)	BL3	-			-	x	x	-	NN	n.a.
	4. Collection of Animal Pathogenic Microorganisms (Brno)	BL3	x			x	-	-	-	NN	n.a.
	5. Institute of Molecular Pathology (Hradec Králové)	BL3	x			x	-	x	-	NN	n.a.
	6. Central Military Health Institute, Department Těchonín (Těchonín)	BL4	x			x	-	x	x	NN	n.a.
	7. Central Military Health Institute, Department Prague (Prague)	BL2	-			-	-	x	-	NN	n.a.
	8. Laboratory for Biological Monitoring and Protection (Milín)	BL4	x			x	-	x	x	NN	n.a.
	9. Laboratory of Molecular Biology (Hradec Králové)	BL2	x			x	-	-	-	NN	n.a.

Country	Name and location of facilities declared in CBM Form A, part 1	Cont. level	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	MoD funded in 2013?	
	10. Division of Infectious Diseases, Department of Infectious Diseases and Epizootology, Faculty of Veterinary Medicine (Brno)	BL3	x			x	-	x	-	NN	n.a.	
	11. National Institute of Public Health; Centre of Epidemiology and Microbiology (Šrobárova)	BL3	-			-	-	x	-	NN	n.a.	
	12. Bioveta, a.s. (Ivanovice na Hané)	BL3	-			-	-	x	-	NN	n.a.	
Denmark	1. Centre for Biosecurity and Biopreparedness (Copenhagen)	BL2		x	x		x	-	ND		n.a.	
	2. Anonymous larger university in Denmark (<i>no location provided</i>)	BL3		-	-		-	x	ND		n.a.	
	3. TB Vaccine Research (Copenhagen)	BL3		-	-		-	x	ND		n.a.	
	4. QC Bio (Copenhagen)	BL3		-	-		-	x	ND		n.a.	
	5. International Reference Laboratory of Mycobacteriology (Copenhagen)	BL3		-	-		-	x	ND		n.a.	
Ecuador	<i>Nothing to declare</i>	n.a.						ND			n.a.	
Estonia	<i>Nothing to declare</i>	n.a.					ND	ND			n.a.	
Finland	1. Centre for Biothreat Preparedness (Helsinki)	BL3	x	x	x	x	x	x	x	x	partly	
	2. National Institute for Health and Welfare, Bacteriological and Virological Lab (Helsinki, Turku)	BL3	x	x	x	x	x	x	x	x	no	
	3. Yersinia Research Laboratory (Helsinki, Turku)	BL2	x	x	x	x	x	x	x	x	partly	
	4. Department of Virology, University of Helsinki (Helsinki)	BL3	x	x	x	x	x	x	x	x	partly	
	5. Institute of Biotechnology (Helsinki)	BL3	-	-	-	-	-	-	-	-	x	no
	6. Finnish Food Safety Authority (Helsinki)	BL3	-	x	x	x	x	x	x	x	x	no
	7. Finnish Defence Forces Technical Research Centre (Lakiala)	BL2 ¹	-	x	x	x	x	x	x	x	x	wholly
Georgia	1. National Center for Disease Control and Public Health (Tbilisi)	BL2				x	x	x			no	
	2. Laboratory of Ministry of Agriculture of Georgia (Tbilisi)	BL2				-	x	x			no	
Germany	1. Bernhard-Nocht-Institut für Tropenmedizin (Hamburg)	BL4	x	x	x	x	x	x	x	x	no	
	2. Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health (Insel Riems)	BL4 ²	x	x	x	x	x	x	x	x	no	
	3. Institut für Virologie der Philipps Universität Marburg (Marburg)	BL4	x	x	x	x	x	x	x	x	partly	
Greece	1. University of Crete School of Medicine (Heraklion)	BL3						x	NN	NN	-	
	2. Kapodistrian University of Athens School of Medicine (Athens)	BL3						x	NN	NN	-	

¹A CB-deployable laboratory is equipped with a BSL-3 glovebox, but was used at BSL2 level during 2011.

²Maximum containment facility not suitable for work with human pathogens.

Country	Name and location of facilities declared in CBM Form A, part 1	Cont. level	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	MoD funded in 2013?
	3. Aristotelian University of Thessaloniki (Thessaloniki)	BL3						x	NN	NN	-
	4. Infectious Diseases Hospital(Thessaloniki)	BL3						x	NN	NN	-
	5. Hellenic Pasteur Institute(Athens)	BL3						x	NN	NN	-
	6. Athens School of Public Health (Athens)	BL3						x	NN	NN	-
Ireland	1. National Virus Reference Laboratory, University College Dublin (Dublin)	BL3+	x	x	x	x	x	x			n.a.
	2. Public Health Laboratory (Dublin)	BL3	x	x	x	x	x	x			n.a.
Japan	1. Murayama Annex of National Institute of Infectious Diseases (Tokyo)	BL4							x	x	no
	2. Riken Tsukuba Institute (Ibaraki)	BL4							-	x	no
Latvia	1. National Microbiology Reference Laboratory (Riga)	BL3						x	x	x	no
	2. Centre for Disease Prevention and Control of Latvia (Riga)	-						-	x	-	no
Liechtenstein	<i>Nothing new to declare</i>	-		NN	NN	NN	NN	NN		NN	n.a.
Lithuania	1. Microbiological laboratory of Vilnius Public Health Centre (Vilnius)	BL3	x	x	x	x	x	-	-	-	n.a.
	2. Laboratory of Centre for Communicable Diseases and AIDS (Vilnius)	BL2	x	x	x	x	x	-	-	-	n.a.
	3. National Food and Veterinary Risk Assessment Institute (Vilnius)	BL3	x	x	x	x	x	x	x	x	no
	4. National Public Health Surveillance Laboratory (Vilnius)	BL3	-	-	-	-	-	x	x	x	no
Madagascar	-	-							-		n.a.
Malaysia	1. Biotechnology Research Institute, Universiti Malaysia Sabah (Kota Kinabalu)	BL3	-					x			n.a.
	2. Medical Laboratories for Medical Microbiology, Parasitology and Virology, University of Putra Malaysia (Serdang)	BL2	-					x			n.a.
	3. Institute of Systems Biology, Universiti Kebangsaan (Bangi)	BL2	-					x			n.a.
	4. Veterinary Research Institute (Ipoh)	BL3	-					x			n.a.
	5. Science and Technology Research Institute for Defence (Kajang)	“normal”	x					-			n.a.
Netherlands	1. TNO Department of CBRN Protection	BL4								x	wholly
New Zealand	National Centre for Biosecurity and Infectious Disease(Upper Hutt)	BL3+	x	x	x		x	x	x	-	no
Norway	Institute of Microbiology, Armed Forces Medical Services (Oslo)	BL3			x		x	x	x	x	wholly
Portugal	1. Laboratório de Bromatologia e Defesa Biológica (Lisbon)	BL3					x	x	x	-	n.a.
	2. Unidade de reposta a Emergências e Biopreparação (Lisbon)	BL3					x	x	-	-	n.a.
	3. Departamento de Doenças Infecciosas (Lisbon)	BL3					-	-	x	x	no

Country	Name and location of facilities declared in CBM Form A, part 1	Cont. level	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	MoD funded in 2013?
	4. Laboratório Nacional De Investigação Veterinária (Lisbon)	BL3					-	-	x	x	no
	5. Unidade de reposta a Emergências e Biopreparação (Braga)	BL3					-	-	-	x	no
Quatar	<i>Nothing new to declare</i>	-							ND		n.a.
Republic of Moldova	1. National Center for Public Health (Chisinau)	BL3							x	NN	no
	2. Republican Center for Veterinary Diagnostics (Chisinau)	BL2							x	NN	no
Romania	1. Laboratory of Microbiology and Epidemiology, Military Medical Research Center (Bucharest)	BL2			NN	x	NN	x	x	x	wholly
Serbia	<i>Nothing to declare</i>	BL2							x		n.a.
Sweden	1. Swedish Defence Research Agency Division of NBC Defence (Umeå)	BL3	x	x	x	x	x	x	-	-	n.a.
	2. Sakerhetslaboratorium, Swedish Institute of Infectious Disease Control (Solna)	BL4	x	x	x	x	x	x	x	x	no
	3. National Veterinary Institute (Uppsala)	BL3	x	x	x	x	x	x	-	-	n.a.
Switzerland	1. Labor Spiez (Spiez)	BL3	NN	NN	NN	NN	x	x	x	x	partly
	2. Institute of Virology and Immunoprophylaxis (Mittelhäusern)	BL3	NN	NN	NN	NN	x	x	x	x	no
	3. National Reference Center for Emerging Viral Infections (Geneva)	BL4 ³	NN	NN	NN	NN	x	x	x	x	no
Thailand	<i>Nothing new to declare</i>	-					NN	NN	NN		-
Turkey	1. Ankara University Biotechnology Institute (Ankara)	BL2						x	x		no
	2. Refik Saydam National Public Health Agency (Ankara)	BL3						x	-		n.a.
	3. Bornova Veterinary Control and Research Institute (Ankara)	BL3						x	-		n.a.
	4. Diagnosis of Poultry Disease Laboratory (Ankara)	BL3						x	-		n.a.
	5. Biosafety Level-3 Laboratory Institute	BL3						-	x		no
Ukraine	1. Governmental Scientific Oversight Institute for Biotechnology and Microorganism Culture Collection (Kiev)	⁴						x	x		no
	2. Mechnikov Institute for Microbiology and Immunology (Charkov)	⁵						x	x		no
	3. Gromashevsky Institute for Epidemiology and Infectious Diseases (Kiev)	⁶						x	x		no
	4. Mechnikov Scientific Research Anti-Plague Institute (Odessa)	BL3						x	x		no

³The BSL-4 unit is approved for diagnostic purposes only.

⁴Ukraine declared four units with an overall floorspace of 780 sqm, without indicating the containment level.

⁵BL4 does not exist; highest level of containment is not indicated (until 2011); BL3 and BL4 do not exist (2012).

⁶BL4 does not exist; highest level of containment is not indicated.

Country	Name and location of facilities declared in CBM Form A, part 1	Cont. level	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	MoD funded in 2013?	
	5. Central Sanitary Epidemiological Station (Kiev)	BL3						x	x		no	
	6. Lvov Scientific Research Institute for Epidemiology and Hygiene (Lvov)	BL3 ⁷						x	x		no	
	7. Anti-Plague Station (Simferopol)	BL3						x	x		no	
	8. Institute for Experimental and Clinical Veterinary Medicine (Charkov)	BL2						-	x		no	
	9. Institute for Veterinary Medicine (Kiev)	- ⁸						-	x		no	
United Kingdom	1. Defence Science and Technology Laboratory (Porton Down, Salisbury)	BL4	x	x	x	x	x	x	x	x	partly	
	2. Health Protection Agency (Colindale, London)	BL4	x	x	x	x	x	x	x	x	no	
	3. Health Protection Agency, Centre for Emergency Preparedness and Response (Salisbury)	BL4	x	x	x	x	x	x	x	-	no	
	4. National Institute for Biological Standards and Control (Potters Bar)	BL4	x	x	x	x	x	x	x	x	no	
	5. National Institute for Medical Research (London)	BL4	x	x	x	x	x	x	x	x	no	
	6. The Pirbright Institute (Pirbright)	BL4	-	-	-	-	-	-	-	-	x	no
	7. Veterinary Laboratories Agency (Addlestone)	SAPO4 ⁹	x	x	x	x	x	x	x	x	x	no
	8. Institute for Animal Health, Pirbright Laboratory (Woking)	SAPO4 ⁸	x	x	x	x	x	x	x	x	-	n.a.
	9. Merial Animal Health (Pirbright)	SAPO4 ⁸	-	-	x	x	x	x	x	x	x	no
	10. Schering-Plough Animal Health (Uxbridge)	SAPO4 ⁸	-	-	x	-	-	-	-	-	-	n.a.
USA	1. Viral Immunology Center, Georgia State University (Atlanta, GA)	BL4					x	x	x	x	no	
	2. The Betty Slick and Lewis J. Moorman, Jr. Laboratory Complex (San Antonio, TX)	BL4					x	x	x	x	partly	
	3. Galveston National Laboratory (Galveston, TX)	BL4					x	x	x	x	partly	
	4. Plum Island Animal Disease Center (Greenport, TX)	BL3					x	x	-	-	n.a.	
	5. U.S. Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD)	BL4					x	x	x	x	wholly	
	6. National Biodefense Analysis and Countermeasures Center (Fort Detrick, MD)	BL4					-	-	x	x	no	
	7. Integrated Research Facility (IRF) – Rocky Mountain Laboratories (Hamilton, MT)	BL4					x	x	-	-	n.a.	
	8. National Institutes of Health (NIH) - NIAID-Rocky Mountain Laboratories (Hamilton, MT)	BL4					-	-	x	x	no	
	9. Coordinating Center for Infectious Diseases (Atlanta, GA)	BL4					x	-	-	-	n.a.	
	10. CDC, Office of Infectious Diseases (Atlanta, GA)	BL4					-	-	x	x	no	

⁷Until 2011, Ukraine declared three units with an overall floorspace of 1,273 sqm, without indicating the containment level.

⁸Ukraine declared four units with an overall floorspace of 780 sqm, without indicating the containment level.

⁹Specified Animal Pathogens Order.

The following table summarizes the data declared in **CBM Form A, part 2 (ii) and (iii)** of the publicly available CBM submissions from 2011 and compares them with the information in publicly available CBMs from 2006 to 2011. The table indicates the overall funding for the biodefence programme as declared in CBM Form A, part 2 (ii), and lists the names and locations of biodefence facilities declared in CBM Form A, part 2 (iii), specifying the year(s) they were declared. Grey cells indicate that there was no CBM submission or that it was not made publicly available in the respective year. “ND” indicates that the state ticked the “Nothing to declare” box in Form 0. “NN” indicates that the state ticked the “Nothing new to declare” box in Form 0. “-” indicates that no data were provided.

Country	Total funding in million EUR ¹⁰								Name and location of biodefence facilities declared in CBM Form A, Part 2 (iii)	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
	2006	2007	2008	2009	2010	2011	2012	2013									
Australia	1.2	1.5	1.6	1.9	1.7	1.7	2.0	2.5	Human Protection and Performance Division, DSTO (Fishermans Bend)	x	x	x	x	x	x	x	x
Austria				0.01	0.03	0.05	0.03	0.02	Armament and Defence Technology Agency (Mödling)				x	x	x	x	x
Belgium						0.6	1.0	0.3	1. Centre de Technologies Moléculaires Appliquées (Brussels)						x	x	x
									2. Université Catholique de Louvain (Louvain-La-Neuve)						x	x	x
									3. Defense Laboratory Department (Vilvoorde)						x	x	x
									4. Research Laboratory for Vector Borne Disease (Brussels)						x	-	-
Bulgaria		-	-		-	-	NN	NN	National Center of Infectious and Parasitic Diseases, Ministry of Health (Sofia)		x	x		x	x	x	x
Canada						6.0+	3.9 ¹¹	6.9	1. Defence R&D Canada (Suffield)						x	x	x
									2. Defence R&D Canada (Valcartier)						x	x	x
Cyprus						ND	ND		<i>Nothing to declare</i>						ND	ND	
Czech Rep.									1. Central Military Health Institute, department Těchonín (Těchonín)	-			-	-	x	x	-
									2. Central Military Health Institute, department Prague (Prague)	-			-	-	x	x	x
									3. Institute of Molecular Pathology (IMP) (Hradec Králové)	-			-	-	x	x	x
									4. Laboratory for biological monitoring and protection (Mlín)	-			-	-	x	x	-
Denmark		1.9	2.0		2.9	2.8	2.7		Centre for Biosecurity and Biopreparedness (Copenhagen)		x	x		x	x	x	
Ecuador						ND			<i>Nothing to declare</i>						ND		

¹⁰ National currencies were converted to Euros using the online service, <http://www.finanzen.net/waehrungsrechner>. 15 April of each respective year, the deadline for submitting the CBM to the UN, was selected as the date for the currency conversion.

¹¹ It is estimated that in 2011/2012, the amount spent on the Canadian biological defence program was \$5,039,000.

Country	Total funding in million EUR ¹⁰								Name and location of biodefence facilities declared in CBM Form A, Part 2 (iii)	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013			
	2006	2007	2008	2009	2010	2011	2012	2013												
Estonia					ND	ND			<i>Nothing to declare</i>					ND	ND		n.a.			
Finland	-	-	-	-	-	-	-	-	Centre for Biothreat Preparedness (Helsinki)	x	x	x	x	x	x	x	x			
Georgia				0.3	1.7	1.6			1. National Center for Disease Control and Public Health (Tbilisi)				x	x	x					
									2. Laboratory of Ministry of Agriculture of Georgia (Tbilisi)				-	x	x					
Germany	12.9	11.7	11.2	8.4	9.9	9.5	9.1	9.1	1. NBC-Defence and Self-Protection School of the Bundeswehr (Sonthofen)	x	x	x	x	x	x	x	x			
									2. Bundeswehr Institute of Microbiology (Munich)	x	x	x	x	x	x	x	x	x		
									3. Federal Armed Forces Scientific Institute for Protection Technologies (Munster)	x	x	x	x	x	x	x	x	x	x	x
									4. Central Institute of the Bundeswehr Medical Service (Kiel)	-	-	x	x	-	x	x	x			
Greece						ND	ND	ND	<i>Nothing to declare</i>						ND	ND	ND			
Ireland	-	-	-	-	-	-			“no national programme to conduct biological defence R & D ...”	-	-	-	-	-	-					
Japan							1.1	2.3	1. Military Medicine Research Unit, Test & Evaluation Command (Tokyo)							x	x			
Latvia							-	-	-							x	x	x		
Liechtenstein		NN	NN	NN	NN	NN			<i>Nothing new to declare</i>		NN	NN	NN	NN	ND		NN			
Lithuania	ND	ND	ND	ND	ND	ND	ND	ND	<i>Nothing to declare</i>	ND	ND	ND	ND	ND	ND	ND	ND			
Madagascar								ND	<i>Nothing to declare</i>							ND				
Malaysia	ND								<i>Nothing to declare</i>	ND					ND					
Netherlands								1.2 ¹²	1. TNO Prins Maurits Building Department of CBRN Protection								x			
New Zealand	ND	ND	ND		ND	ND	ND	ND	<i>Nothing to declare</i>	ND	ND	ND		ND	ND	ND	ND			
Norway			-		-	-	0.5	-	1. Institute of Microbiology, Armed Forces Medical Services (Oslo)			x		x	x	x	x			
Portugal					0.2	0.2	0.1	0.03	1. Laboratório de Bromatologia e Defesa Biológica (Lisbon)					x	x	x	x			
Quatar								ND	<i>Nothing to declare</i>							ND				
Republic of						0.02	0.02	0.04	1. The National Center of Public Health (Chisinau)						x	x	x			

¹² The biological defence budget for the period 2010-2013 was 3,5 Million Euro.

Country	Total funding in million EUR ¹⁰								Name and location of biodefence facilities declared in CBM Form A, Part 2 (iii)	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
	2006	2007	2008	2009	2010	2011	2012	2013									
Moldova																	
Romania			-	NN	NN	-	0.01	0.01	Military Medical Research Center (Bucharest)			x	NN	NN	x	x	x
Serbia							ND		<i>Nothing to declare</i>							ND	
Sweden	2.8	2.8	2.7	2.7	3.1	3.5	3.7	6.6	Swedish Defence Research Agency (Umea)				x	x	x	x	x
									National Veterinary Institute (Uppsala)				-	-	-	-	x
Switzerland	0.6	0.6	0.6	1.0	1.7	3.9	4.2	4.1	1. Spiez Laboratory, Swiss NBC Defence Establishment (Spiez)	x	x	x	x	x	x	x	x
2. Institute of Virology and Immunoprophylaxis (Mittelhäusern)									-	-	-	-	x	x	x	x	
3. National Reference Center for Emerging Viral Infections (Geneva)									-	-	-	-	x	x	x	x	
4. National Reference Center for Anthrax (Bern)									-	-	-	-	x	x	x	x	
5. Bacteriological Laboratory Regional Competence Center- Regional Laboratory West (Geneva)									-	-	-	-	x	x	x	x	
6. Virological Laboratory Regional Competence Center- Regional Laboratory West (Geneva)									-	-	-	-	x	x	x	x	
7. Diagnostic Laboratories of the Institute of Microbiology- Regional Competence Center- Regional Laboratory West (Lausanne)									-	-	-	-	x	x	x	x	
8. Labor Spiez- Regional Competence Center- Regional Laboratory West Central (Spiez)									-	-	-	-	x	x	x	x	
9. Department of Medical Microbiology- Regional Competence Center- Regional Laboratory East Central (Luzern)									-	-	-	-	x	x	x	x	
10. Institute of Medical Microbiology – Regional Competence Center- Regional Laboratory East (Zurich)									-	-	-	-	x	x	x	x	
11. Institute for Medical Virology- Regional Competence Center- Regional Laboratory East (Zurich)									-	-	-	-	x	x	x	x	
12. Cantonal Laboratory of Basel-Stadt- Regional Competence Center- Regional Laboratory North (Basel)									-	-	-	-	x	x	x	x	
13. Cantonal Institute of Microbiology- Regional Competence Center- Regional Laboratory South (Bellinzona)									-	-	-	-	x	x	x	x	
Thailand					NN	NN	NN		<i>Nothing new to declare</i>					NN	NN	NN	
Turkey						2.3	NN		1. IDC (Ankara)						x	NN	
									2. Refik Saydam National Public Health Agency (Ankara)						x	NN	
Ukraine						-	-		“A national programme for research and development in biodefence does not exist in Ukraine.” “The Institute for Experimental and Clinical Veterinary Medicine conducts research into standard operating procedures for biosecurity and biodefence.” (2012) <i>(Authors translation)</i>						-	-	

Country	Total funding in million EUR ¹⁰								Name and location of biodefence facilities declared in CBM Form A, Part 2 (iii)							
	2006	2007	2008	2009	2010	2011	2012	2013	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
UK	73.6	75.0	77.6	65.7	53.6	57.8	62	60.1	Defence Science and Technology Laboratory (Porton Down, Salisbury)	x	x	x	x	x	x	x
USA					451.6	475.2	779	743	1. Plum Island Animal Disease Center (Greenport, TX)				x	x	x	x
									2. Tyndall AFB, Research Road (Tyndall, FL)				x	x	x	x
									3. Tyndall AFB, Barnes Drive (Tyndall, FL)				x	x	x	x
									4. Lothar Salomon Life Sciences Test Facility (Dugway, UT)				x	x	x	-
									5. U.S. Army Edgewood Chemical and Biological Center (Aberdeen, MD)				x	x	x	x
									6. U.S. Army Medical Research Institute of Chemical Defense (Aberdeen, MD)				x	x	x	x
									7. U.S. Army Medical Research Institute of Infectious Diseases (Fort Detrick, MD)				x	x	x	x
									8. Walter Reed Army Institute of Research (Silver Spring, MD)				x	x	x	-
									9. Battelle Biomedical Research Center (West Jefferson, OH)				x	x	-	-
									10. Naval Surface Warfare Center – Dahlgren Division (Dahlgren, VA)				x	x	x	-
									11. Naval Research Laboratory (Washington, DC)				x	x	x	x
									12. Naval Medical Research Center (Silver Springs, MD)				x	x	x	x
									13. Brookhaven National Laboratory (Upton, NY)				x	x	x	x
									14. Idaho National Laboratory (Idaho Falls, ID)				x	x	x	x
									15. Los Alamos National Laboratory (Los Alamos, NM)				x	x	x	x
									16. Lawrence Livermore National Laboratory (Livermore, CA)				x	x	x	x
									17. Oak Ridge National Laboratory (Oak Ridge, TN)				x	-	-	-
									18. Pacific Northwest National Laboratory (Richland, WA)				x	x	x	x
									19. Sandia National Laboratories (Albuquerque, NM)				x	x	x	x
									20. C.W Bill Young Center for Biodefense and Emerging Infectious Diseases (Bethesda, MD)				x	x	x	x
									21. Integrated Research Facility- Rocky Mountain laboratories (Hamilton, MT)				x	x	x	x
									22. Dale and Betty Bumpers Vaccine Research Center (Betasda, MD)				x	x	x	x
									23. Coordinating Center for Infectious Diseases (Atlanta, GA)				x	x	-	-
									24. Division of Vector-borne Infectious Diseases, CDC (Fort Collins, CO)				x	x	x	x
									25. Mass Spectrometry Toxin Laboratory, CDC (Atlanta, GA)				x	x	-	-
									26. Foreign Disease-Weed Science Research Unit (Fort Detrick, MD)				x	x	x	x
									27. National Animal Disease Center (Ames, IA)				x	x	x	x
									28. Southeast Poultry Research Laboratory (Athens, GA)				x	x	x	x

Country	Total funding in million EUR ¹⁰								Name and location of biodefence facilities declared in CBM Form A, Part 2 (iii)	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
	2006	2007	2008	2009	2010	2011	2012	2013									
									29. National Biodefense Analysis and Countermeasures Center (Fort Detrick, MD)					-	x	x	x
									30. Office of Infectious Diseases, CDC (Atlanta, GA)					-	x	x	x
									31. Lawrence Berkeley National Laboratory (Berkeley, CA)					-	-	x	x
									32. National Center for Environmental Health (Atlanta, GA)					-	-	x	x
									33. Air Force Research Laboratory (Wright-Patterson Air Force Base, OH)					-	-	-	x
									34. Lothar Salomon Test Facility (Dugway, UT)					-	-	-	x

The following table summarizes the data declared in **CBM Form G** of the publicly available CBM submissions from 2012 and compares them with the information in publicly available CBMs from 2006 to 2011. It provides the names and locations of vaccine production facilities declared in CBM Form G, the year(s) they were declared, and the diseases against which vaccines were produced. Grey cells indicate that there was no CBM submission or that it was not made publicly available in the respective year. “ND” indicates that the state ticked the “Nothing to declare” box in Form 0. “NN” indicates that the state ticked the “Nothing new to declare” box in Form 0. “-” indicates that no data were provided.

Country	Name and location of vaccine production facilities declared in CBM Form G	Cat. A diseases ¹³	Other diseases	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
Australia	1. CSL Limited (Parkville)	no	yes	x	x	x	x	x	x	x	x
	2. Q-Gen Ltd. (<i>no location provided</i>)	no	yes	-	-	-	x	x	x	-	-
	3. Ludwig Institute for Cancer Research (Heidelberg, VIC)	no	yes	-	-	-	x	x	x	x	x
	4. Queensland Institute of Medical Research (Queensland)	no	no	-	-	-	-	-	-	x	x
Austria	<i>Nothing to declare</i>	n.a.	n.a.				ND	ND	ND	ND	ND
Belgium	1. GlaxoSmithKline Biologicals S.A (Rixensart)	_14	_14						x	x	x
	2. Pfizer Animal Health (Louvain-la-Neuve)	_14	_14						x	-	-
Bulgaria	1. BulBio- NCIPD Ltd (Sofia)	Haem fevers	yes		x	x		x	x	x	x
	2. National Diagnostic and Research Veterinary Medical Institute (Sofia)	Anthrax	yes		-	-		x	-	-	-
Canada	1. Artemis Technologies Inc. (Guelph)	no	yes						x	x	x
	2. Bioniche Life Sciences Inc. (Belleville)	no	yes						x	x	x
	3. Gallant Custom Laboratories Inc. (Cambridge)	no	yes						x	x	x
	4. Pfizer Animal Health (Saanichton)	no	yes						x	x	x
	5. Novartis Animal Health Canada Inc. (Mississauga)	no	yes						x	x	x
	6. Novartis – Aqua Health (Charlottetown and Victoria)	no	yes						x	x	x
	7. Nutratech Inc. (Winnipeg)	no	yes						x	x	x
	8. Saskatchewan Research Council (Saskatoon)	no	yes						x	x	x
	9. Saskatoon Colostrum Co. Ltd. (Saskatoon)	no	yes						x	x	x
	10. Vetovac Ltée. (Saint-Hyacinthe)	no	yes						x	x	x
	11. Vetech Laboratories Inc. (Guelph)	no	yes						x	x	-
	12. Biovet Inc. (Saint-Hyacinthe)	no	yes						x	x	x
	13. Intervet Canada Corp. (Kirkland)	no	yes						x	x	-

¹³As designated by the Centers for Disease Control and Prevention (CDC) in the USA.

¹⁴This information is not provided in the public version of the CBM.

Country	Name and location of vaccine production facilities declared in CBM Form G	Cat. A diseases ¹³	Other diseases	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
	14. Vétoquinol N.A. Inc. (Lavaltrie)	no	yes						x	x	-
	15. ID Biomedical Corporation of Quebec (GlaxoSmithKline Inc.) (Quebec City)	n.a.	yes						-	-	x
	16. Sanofi Pasteur Limited (Toronto)	n.a.	yes						-	-	x
Cyprus	<i>Nothing to declare</i>	n.a.	n.a.						ND	ND	
Czech Republic	1. Baxter BioScience s.r.o (Kostolec nad Černými Lesy)	no	yes	x			NN	ND	x	NN	NN
	2. Sevapharma a.s. (Prague)	no	yes	x			NN	ND	x	NN	NN
	3. Bioveta a.s. (Ivanovice nad Hané)	Anthrax	yes	x			NN	ND	x	NN	NN
	4. Dyntec s.r.o. (Terezín)	no	yes	x			NN	ND	x	NN	NN
	5. BIOPHARMA, Research Institute of Biopharmacy and Veterinary Drugs (Jíluvě u Prahy)	no	yes	x			NN	ND	x	NN	NN
Denmark	1. Statens Serum Institute (Copenhagen)	no	yes		x	x		NN	x	x	
	2. Bavarian Nordic A/S (Kvistgard)	Smallpox	yes		x	x		NN	x	x	
Ecuador	<i>Nothing to declare</i>	n.a.	n.a.						ND		
Estonia	<i>Nothing to declare</i>	n.a.	n.a.					ND	ND		n.a.
Finland	<i>Nothing to declare</i>	n.a.	n.a.	NN	NN	NN	NN	NN	ND	ND	ND
Georgia	<i>Nothing to declare</i>	n.a.	n.a.				ND	ND	ND		
Germany	1. Novartis Vaccines and Diagnostics GmbH & Co. KG (Marburg)	Botulism	yes	x	x	x	x	x	x	x	NN
	2. GlaxoSmithKline Biologicals (Dresden)	no	yes	x	x	x	x	x	x	x	NN
	3. IDT Biologika GmbH (Rosslau)	Smallpox	yes	x	x	x	x	x	x	x	NN
	4. Rhein Biotech GmbH (Düsseldorf)	no	yes	-	-	-	-	x	x	x	NN
	5. Bavaria Nordic GmbH (Berlin)	Smallpox	no	-	-	-	-	x	x	x	NN
	6. Vibalogics GmbH (Cuxhaven)	no	yes	-	-	-	-	-	-	x	NN
Greece	<i>Nothing to declare</i>	n.a.	n.a.						ND	ND	ND
Ireland	1. Elanco Laboratories (Sligo) ¹⁵	-	-	x	x	x	x	x	x		
Japan	1. Denka Seiken Co., Ltd (Tokyo)	no	yes							x	x
	2. Kitasato Daiichi Sankyo Vaccine Co., Ltd (Saitama)	no	yes							x	x
	3. Takeda Pharmaceutical co., Ltd (Osaka)	no	yes							x	x

¹⁵Not currently active but maintains capacity to produce human or animal vaccines.

Country	Name and location of vaccine production facilities declared in CBM Form G	Cat. A diseases ¹³	Other diseases	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013	
	4. Research Foundation for Microbial Diseases of Osaka University (Osaka)	no	yes							x	x	
	5. Chemo-Sero-Therapeutic Research Institute (Kumamoto)	Smallpox	yes							x	x	
	6. Japan BCG Laboratory (Tokyo)	no	yes							x	x	
	7. Japan Poliomyelitis Research Institute (Tokyo)	no	yes							x	x	
Latvia	<i>Nothing to declare</i>	-	-						-	ND	ND	
Liechtenstein	<i>Nothing new to declare</i>	-	-		NN	NN	NN	NN	NN		NN	
Lithuania	<i>Nothing new to declare</i>	-	-	NN	NN	NN	NN	NN	NN	NN	NN	
Madagascar	-	-	-							-		
Malaysia	1. Institute of Veterinary Services (Putrajaya)	no	yes						x			
Netherlands	1. Central Veterinary Institute, part of Wageningen UR (Lelystad)	no	yes								x	
	2. MSD Animal Health (Boxmeer)	no	yes								x	
	3. Nederlands Vaccin Instituut (Bilthoven)	no	yes								x	
	4. WWP (Weesp)	no	yes								x	
	5. Boehringer Ingelheim Animal Health Operation (Weesp)	n.a.	n.a.									x
	6. Crucell Holland (Leiden)	no	yes									x
New Zealand	<i>Nothing to declare</i>	n.a.	n.a.	ND	ND	ND		ND	ND	ND	ND	
Norway	1. Alpharma (Overhalla)	no	yes			x		x	x	x	x	
	2. The National Veterinary Institute (Oslo)	no	yes			x		x	x	x	x	
	3. Norwegian Institute of Public Health (Nydalen)	no	yes			x		x	x	x	x	
Portugal	1. Genibet Biopharmaceuticals	no	yes					ND	ND	x	x	
Quatar	<i>Nothing to declare</i>	n.a.	n.a.							ND		
Republic of Moldova	<i>Nothing to declare</i>	n.a.	n.a.						ND	ND	ND	
Romania	1. "Cantacuzino" National Institute of R&D for Microbiology and Immunology (Bucharest)	no	yes			-	-	x	NN	x	x	
	2. National Society Pasteur Institute S.A. (Bucharest)	no	yes			x	x	-	NN	x	x	
	3. S.C. Pasteur Filiala Filipești S.R.L. (Prahova)	no	yes			-	-	-	-	-	x	
	4. S.C. Romvac Company S.A. (Voluntari)	no	yes			-	-	-	-	-	x	
Serbia	Institute of Immunology and Virology "Torlak" (Belgrad)	no	yes							x		

Country	Name and location of vaccine production facilities declared in CBM Form G	Cat. A diseases ¹³	Other diseases	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
Sweden	1. SBL Vaccin AB (Solna)	no	yes	x	x	x	x	x	x	-	NN
	2. UniTech Biopharma (Matfors)	no	yes	x	x	x	x	x	x	-	NN
	3. Cobra Biopharma (Matfors)	no	yes	-	-	-	-	-	-	x	NN
	4. Crucell Sweden AB (Stockholm)	no	yes	-	-	-	-	-	-	x	x
Switzerland	1. Crucell Switzerland AG (Bern)	no	yes	NN	NN	NN	NN	x	x	x	x
	2. Cytos Biotechnology AG (Schlieren)	no	no	NN	NN	NN	NN	x	x	x	-
	3. Pevion Biotech Ltd. (Ittingen)	no	yes	NN	NN	NN	NN	x	x	x	x
Thailand	1. The Government Pharmaceutical Organisation (Bangkok)	no	yes					x	x	x	
	2. Merieux Biological Products Co., Ltd. (Chachoengsao)	no	yes					-	-	x	
	3. Queen Saovabha Memorial Institute (Bangkok)	no	yes					-	-	x	
	4. BioNet-Asia Co., Ltd. (Bangkok)	no	yes					-	-	x	
	5. Bureau of Veterinary, Department of Livestock Development (Nakhon Ratchasima)	Anthrax	yes					-	-	x	
Turkey	1. Konya Veterinary Control and Research Institute (Meram-Konya)	no	yes						x	NN	
	2. Pendik Veterinary Control and Research Institute (Pendik-Istanbul)	no	yes						x	NN	
	3. Central Veterinary Control and Research Institute (Ankara)	Anthrax	yes						x	NN	
Ukraine	1. Biofabrika Suma (Suma)	Anthrax	yes						x	x	
	2. Biofabrika Dnepropetrovsk (Dnepropetrovsk)	no	yes						x	x	
	3. Biofabrika Charkov (Charkov)	no	yes						x	x	
	4. Biofabrika Cherson (Cherson)	Anthrax	yes						x	x	
	5. Biofabrika Novogalechinsk (Kiev)	no	yes						x	x	
	6. OOO "Ukrvetpromsnab" (Brovar)	no	yes						x	x	
	7. Corporation "Ukrzoovetpromsnab" (Kiev)	no	yes						x	x	
	8. Institute for Experimental and Clinical Veterinary Medicine(Charkov)	no	yes						x	x	
	9. Institute for Veterinary Medicine of the National Academy of Science (Kiev)	no	yes						x	x	
	10. Closed Joint Stock Company "Biolek" (Charkov)	no	yes						x	-	
	11. Pharmalife GmbH (Lvov)	no	yes						x	-	
	12. Open Joint Stock Company "Pharmak" (Kiev)	no	yes						x	-	
United	1. Health Protection Agency, Centre for Emergency Preparedness and Response (Salisbury)	Anthrax	no	x	x	x	x	x	x	x	x

Country	Name and location of vaccine production facilities declared in CBM Form G	Cat. A diseases ¹³	Other diseases	Decl. 2006	Decl. 2007	Decl. 2008	Decl. 2009	Decl. 2010	Decl. 2011	Decl. 2012	Decl. 2013
Kingdom	2. MedImmune (Liverpool)	no	yes	x	x	x	x	x	x	x	x
	3. Novartis Vaccines and Diagnostics Limited (Liverpool)	no	yes	x	x	x	x	x	x	x	x
USA	1. Emergent BioDefense Operations Lansing Inc. (Lansing, MI)	Anthrax	no					x	x	x	x
	2. MassBiologics (Boston, MA)	no	yes					x	x	x	x
	3. Med Immune LLC (Gaithersburg, MD)	no	yes					x	x	x	x
	4. Merck & Co, Inc. (Whitehouse Station, NJ)	no	yes					x	x	x	x
	5. Organon Teknika Corporation LLC (Durham, NC)	no	yes					x	x	x	x
	6. Sanofi Pasteur Inc. (Swiftwater, PA)	no	yes					x	x	x	x
	7. Sanofi Pasteur Biologics Co. (Cambridge, MA)	Smallpox	no					x	x	x	x
	8. Wyeth Pharmaceuticals Inc. (New York, NY)	no	yes					x	x	x	x
	9. Barr Laboratories, Inc. (Forrest, VA)	no	yes					-	-	x	x
	10. Protein Sciences Corporation (Meriden, CT)	no	yes					-	-	-	x

Research Group for Biological Arms Control

The aim of the Research Group is to contribute, through innovative research and outreach activities, to the universal prevention of biological weapons development, production and use. The focus of activities is twofold. Firstly, the Research Group contributes to preventing the erosion of the universal bioweapons prohibition by opposing norm-harming activities. Secondly, it develops new concepts and instruments for monitoring bioweapon relevant activities and for verifying and enforcing compliance with the norm against bioweapons.

Contact

Research Group for Biological Arms Control
C. F. v. Weizsäcker Centre for Science and Peace Research • University of Hamburg
Beim Schlump 83 • 20144 Hamburg • Germany
Tel +49 40 42838 4383 • Fax +49 40 42838 3052 • E-mail info@biological-arms-control.org
www.biological-arms-control.org